Stockhub

Prescient Therapeutics Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

24 September 2022

  • curprev 09:1009:10, 24 September 2022‎ Nick talk contribs‎ 964 bytes +964‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological a..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Prescient_Therapeutics_Limited’